Skip to main content

Biomarker Predictors of Memantine Sensitivity

Recruiting

This study will test the effects of memantine on brain function and dementia symptoms in older adults with mild to moderate Alzheimer's disease who are not currently taking Alzheimer's medications. 

Minimum Age Maximum Age Gender Healthy Volunteers
50 Years 80 Years All No
January 31, 2019
August 2023
88

  • Diagnosis of Alzheimer's disease
  • Mini-Mental State Examination score of 10 to 22 or Montreal Cognitive Assessment score of 15 to 24
  • Knowledgeable caregiver
  • Able to walk
  • Medically stable
  • Pass hearing test

  • Active systemic illness (e.g., heart disease, liver failure, kidney insufficiency, cancer, HIV, tuberculosis, hepatitis C)
  • Current psychiatric or neurological illness other than Alzheimer's disease
  • History of vascular disease, heart attack, cerebrovascular accidents, mini-stroke, seizure, head injury with loss of consciousness
  • History of substance dependence, including alcohol and opioids
  • Past treatment with memantine or unable to take an acetylcholinesterase inhibitor
  • Participated in an investigational drug treatment within 30 days of screening
  • Prohibited medications: amantadine, riluzole, other pro-cognitive drugs, opioids
  • Positive urine test for nonprescribed psychoactive substance
  • Actively enrolled in cognitive remediation therapy

Memantine, also known as Namenda, is a drug approved by the U.S. Food and Drug Administration to treat moderate to severe symptoms of the disease. In this study participants will be randomly assigned to take either memantine (20 mg) or a placebo twice daily for about 6 weeks.

Name City State Zip Status Primary Contact
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego California 92103 Recruiting Jo Talledo, B.A.
619-543-3093
atalledo@ucsd.edu

University of California, San Diego

Name Role Affiliation
Neal Swerdlow, M.D., Ph.D. Principal Investigator UCSD

Name Phone Email
Jo Talledo Benrubi 619-543-3093 atalledo@ucsd.edu

NCT03703856

Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease